Composition, form of production and packaging
? Capsules 1 caps.
chondroitin sulfate 200 mg
glucosamine hydrochloride 250 mg
10 pieces. - packings cellular planimetric (2) - packs cardboard.
10 pieces. - packings cellular planimetric (3) - packs cardboard.
10 pieces. - packings cellular planimetric (4) - packs cardboard.
10 pieces. - packings cellular planimetric (6) - packs cardboard.
10 pieces. - packings cellular planimetric (5) - packs cardboard.
10 pieces. - packings cellular planimetric (10) - packs cardboard.
10 pieces. - packings cellular planimetric (12) - packs cardboard.
5 pieces. - packings of cellular contour (1) - packs cardboard.
5 pieces. - packings cellular planimetric (2) - packs cardboard.
5 pieces. - packings cellular planimetric (4) - packs cardboard.
5 pieces. - packings cellular planimetric (5) - packs cardboard.
5 pieces. - packings cellular planimetric (6) - packs cardboard.
5 pieces. - packings cellular planimetric (9) - packs cardboard.
5 pieces. - packings cellular planimetric (10) - packs cardboard.
5 pieces. - packings cellular planimetric (12) - packs cardboard.
6 pcs. - packings of cellular contour (1) - packs cardboard.
6 pcs. - packings cellular planimetric (2) - packs cardboard.
6 pcs. - packings cellular planimetric (3) - packs cardboard.
6 pcs. - packings cellular planimetric (4) - packs cardboard.
6 pcs. - packings cellular planimetric (5) - packs cardboard.
6 pcs. - packings cellular planimetric (6) - packs cardboard.
6 pcs. - packings cellular planimetric (9) - packs cardboard.
6 pcs. - packings cellular planimetric (10) - packs cardboard.
6 pcs. - packings cellular planimetric (12) - packs cardboard.
30 pcs. - cans (1) - packs cardboard.
60 pcs. - cans (1) - packs cardboard.
100 pieces. - cans (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
PHARMACHOLOGIC EFFECT
Stimulates the restoration of cartilaginous tissue. Glucosamine and chondroitin sulfate are involved in the synthesis of connective tissue, helping to prevent cartilage destruction processes and stimulating tissue regeneration. The introduction of exogenous glucosamine enhances the production of the cartilage matrix and provides non-specific protection against chemical damage to the cartilage. Glucosamine in the form of a sulfate salt is a precursor of hexosamine, and the sulfate anion is necessary for the synthesis of glycosaminoglycans. Another possible function of glucosamine is to protect the damaged cartilage from metabolic destruction caused by non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticosteroids (GCS), as well as its own moderate anti-inflammatory effect.
Chondroitin sulfate, regardless of whether it is absorbed in intact form or as separate components, serves as an additional substrate for the formation of a healthy cartilage matrix. Stimulates the formation of hyaluronone, the synthesis of proteoglycans and collagen type II, and also protects hyaluronone from enzymatic cleavage (by suppressing the activity of hyaluronidase) and the damaging effect of free radicals; affects the phosphoric-calcium metabolism in the cartilaginous tissue, slows the resorption of bone tissue and reduces the loss of calcium, accelerates the processes of bone repair, inhibits the degeneration of cartilaginous tissue, helps restore the joint bag, cartilage surfaces of the joints, maintains the viscosity of the synovial fluid, plays the role of a kind of lubrication of the joint surfaces, is involved in cartilage repair and inhibits the activity of those enzymes that break down cartilage (elastase, hyaluronidase). In the treatment of osteoarthritis, it alleviates the symptoms of the disease and reduces the need for NSAIDs.
PHARMACOKINETICS
When ingested 90% is absorbed from the gastrointestinal tract (GIT). C max in blood plasma is achieved after 3-4 hours, in synovial fluid - after 4-5 hours Bioavailability in relation to synovial fluid:
- for chondroitin - 13%;
- for glucosamine - 25% (the effect of "first passage" through the liver is expressed).
When chondroitin sodium sulfate is taken orally once in a dose of 0.8 g (or 2 times a day at a dose of 0.4 g), the plasma concentration rises sharply for 24 hours. Absolute bioavailability is 12%.
Glucosamine + chondroitin sulfate is distributed in tissues: the highest concentrations are found in the liver, kidneys and articular cartilage. About 30% of the dose is persistently persistent in bone and muscle tissue. About 10 and 20% of the dose received is absorbed in the form of high molecular weight and low molecular weight derivatives, respectively. The apparent V d is about 0.44 ml / g.
Chondroitin sodium sulfate is metabolized by desulfurization (after administration of low molecular weight chondroitin sodium sulfate). When distributed in tissues, the highest concentrations are found in the liver, kidneys and articular cartilage. About 30% of the dose is persistently persistent in bone and muscle tissue. Glucosamine + chondroitin sulfate is excreted mainly with urine in unchanged form; in part - with feces.
T 1/2 for glucosamine 68 h T 1/2 for chondroitin sulfate 310 min.
INDICATIONS
Osteoarthritis of peripheral joints and spine joints of I-III degree.
DOSING MODE
Inside, 20 minutes before meals, with a small amount of liquid. Assign 2 capsules 3 times a day for the first three weeks; in the following days - 2 capsules 2 times a day. The minimum course of admission is 3 months.
SIDE EFFECT
Glucosamine: a violation of the function of the gastrointestinal tract (epigastric pain, flatulence, diarrhea or constipation), dizziness, allergic reactions, headache, leg pain and peripheral edema, drowsiness, insomnia, tachycardia.
Chondroitin: an allergic reaction.
CONTRAINDICATIONS
Increased individual sensitivity to one of the components of the drug (allergic reaction), pronounced impaired kidney function, pregnancy, lactation, children under 18 years of age.
PREGNANCY AND LACTATION
The drug is contraindicated for use during pregnancy and breastfeeding. If it is necessary to use the drug during lactation, it is recommended to stop breastfeeding.
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in marked violation of kidney function.
APPLICATION FOR CHILDREN
Contraindicated in children under 18 years.
SPECIAL INSTRUCTIONS
If unwanted effects on the part of the gastrointestinal tract appear, the dose should be reduced 2-fold, and if there is no improvement, cancel the drug. If there is no clinical effect after a treatment course of 4 capsules a day for 4 weeks, the diagnosis should be clarified.
Do not exceed the dose recommended by your doctor.
Stable therapeutic effect is achieved with a minimum of 6 months. Against the background of taking the drug, the need for NSAIDs decreases.
OVERDOSE
Symptoms: cases of overdose are unknown.
Treatment: gastric lavage, symptomatic therapy.
DRUG INTERACTION
Increases the absorption of tetracyclines, reduces the effect of semisynthetic penicillins and glucosamine.
The drug is compatible with NSAIDs and GCS.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
In a dry, protected from light place at a temperature of no higher than 25 В° C. Keep out of the reach of children.
Shelf life. 2 years. Do not use after the expiration date printed on the package.
